Clearance of persistent SARS-CoV-2 associates with increased neutralizing antibodies in advanced HIV disease post-ART initiation.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
15 Mar 2024
15 Mar 2024
Historique:
received:
10
08
2023
accepted:
27
02
2024
medline:
18
3
2024
pubmed:
16
3
2024
entrez:
16
3
2024
Statut:
epublish
Résumé
SARS-CoV-2 clearance requires adaptive immunity but the contribution of neutralizing antibodies and T cells in different immune states is unclear. Here we ask which adaptive immune responses associate with clearance of long-term SARS-CoV-2 infection in HIV-mediated immunosuppression after suppressive antiretroviral therapy (ART) initiation. We assembled a cohort of SARS-CoV-2 infected people in South Africa (n = 994) including participants with advanced HIV disease characterized by immunosuppression due to T cell depletion. Fifty-four percent of participants with advanced HIV disease had prolonged SARS-CoV-2 infection (>1 month). In the five vaccinated participants with advanced HIV disease tested, SARS-CoV-2 clearance associates with emergence of neutralizing antibodies but not SARS-CoV-2 specific CD8 T cells, while CD4 T cell responses were not determined due to low cell numbers. Further, complete HIV suppression is not required for clearance, although it is necessary for an effective vaccine response. Persistent SARS-CoV-2 infection led to SARS-CoV-2 evolution, including virus with extensive neutralization escape in a Delta variant infected participant. The results provide evidence that neutralizing antibodies are required for SARS-CoV-2 clearance in HIV-mediated immunosuppression recovery, and that suppressive ART is necessary to curtail evolution of co-infecting pathogens to reduce individual health consequences as well as public health risk linked with generation of escape mutants.
Identifiants
pubmed: 38491050
doi: 10.1038/s41467-024-46673-2
pii: 10.1038/s41467-024-46673-2
pmc: PMC10943233
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2360Subventions
Organisme : Bill & Melinda Gates Foundation
ID : INV-018944
Pays : United States
Informations de copyright
© 2024. The Author(s).
Références
Nature. 1995 Jun 8;375(6531):497-500
pubmed: 7539892
Br J Haematol. 2020 Jul;190(2):185-188
pubmed: 32557623
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
N Engl J Med. 2021 Aug 5;385(6):562-566
pubmed: 34347959
Annu Rev Immunol. 2023 Apr 26;41:343-373
pubmed: 36750314
Nat Immunol. 2022 Feb;23(2):165-176
pubmed: 35105981
Nat Commun. 2021 Feb 19;12(1):1162
pubmed: 33608522
Nature. 2022 Feb;602(7897):487-495
pubmed: 34942634
Science. 2021 Feb 19;371(6531):850-854
pubmed: 33495308
mSphere. 2021 Aug 25;6(4):e0048021
pubmed: 34431691
Cell. 2021 Feb 18;184(4):861-880
pubmed: 33497610
J Exp Med. 1992 Oct 1;176(4):1099-106
pubmed: 1402655
Ann Rheum Dis. 2021 Oct;80(10):1357-1359
pubmed: 33975857
Virus Evol. 2022 Aug 11;8(2):veac050
pubmed: 35996593
Immunity. 2021 Aug 10;54(8):1853-1868.e7
pubmed: 34331873
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
Cell Host Microbe. 2022 Apr 13;30(4):545-555.e4
pubmed: 35364015
Clin Infect Dis. 2018 Mar 4;66(suppl_2):S111-S117
pubmed: 29514238
Nature. 2021 May;593(7857):142-146
pubmed: 33780970
Lancet. 2020 Aug 15;396(10249):467-478
pubmed: 32702298
Sci Transl Med. 2024 Jan 24;16(731):eadk1599
pubmed: 38266109
AIDS. 2023 Jul 15;37(9):1481-1486
pubmed: 37395254
Nature. 2022 Jul;607(7918):356-359
pubmed: 35523247
N Engl J Med. 2020 Nov 12;383(20):1920-1931
pubmed: 32663912
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5
pubmed: 35120605
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
EMBO J. 1995 Feb 1;14(3):546-54
pubmed: 7859743
Virus Evol. 2023 Dec 28;10(1):vead075
pubmed: 38361824
Emerg Microbes Infect. 2022 Dec;11(1):18-29
pubmed: 34818119
Cell Host Microbe. 2021 Mar 10;29(3):463-476.e6
pubmed: 33592168
Clin Infect Dis. 2023 Feb 8;76(3):e522-e525
pubmed: 35793242
Antimicrob Resist Infect Control. 2022 Feb 5;11(1):28
pubmed: 35123573
Lancet Infect Dis. 2021 May;21(5):637-646
pubmed: 33485468
Nat Rev Immunol. 2022 Feb;22(2):69-71
pubmed: 35046570
Cell. 2020 Dec 23;183(7):1901-1912.e9
pubmed: 33248470
Lancet Reg Health Eur. 2021 Sep;8:100164
pubmed: 34278371
Lancet Microbe. 2023 May;4(5):e294-e295
pubmed: 36657480
AIDS. 2022 Oct 1;36(12):1689-1696
pubmed: 35848570
Int J Rheum Dis. 2022 Nov;25(11):1324-1327
pubmed: 35929362
Cell. 2010 Nov 24;143(5):789-801
pubmed: 21111238
Trends Microbiol. 2018 Dec;26(12):986-998
pubmed: 29954653
Ann Rheum Dis. 2021 Oct;80(10):1355-1356
pubmed: 33958323
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Glob Health Action. 2019;12(1):1679472
pubmed: 31679482
Elife. 2018 Mar 20;7:
pubmed: 29555018
Lancet. 2021 Feb 20;397(10275):671-681
pubmed: 33545094
Trends Immunol. 2012 Jun;33(6):306-14
pubmed: 22613276
Nature. 2013 Jun 20;498(7454):376-9
pubmed: 23739328
Lancet. 2020 Sep 26;396(10255):887-897
pubmed: 32896291
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
BMJ Case Rep. 2021 Aug 4;14(8):
pubmed: 34348912
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Cell Rep. 2015 Sep 8;12(10):1555-1563
pubmed: 26321639
Lancet HIV. 2021 Jun;8(6):e334-e341
pubmed: 33933189
N Engl J Med. 2020 Dec 10;383(24):2320-2332
pubmed: 32877576
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Trends Microbiol. 2018 Sep;26(9):781-793
pubmed: 29534854
Transfus Apher Sci. 2020 Oct;59(5):102871
pubmed: 32694044
Clin Microbiol Rev. 1995 Apr;8(2):180-99
pubmed: 7621399
Lancet Infect Dis. 2021 Feb;21(2):181-192
pubmed: 33217362
EBioMedicine. 2022 Apr;78:103944
pubmed: 35465948
Nature. 2014 Jan 23;505(7484):509-14
pubmed: 24356306
Cell Host Microbe. 2024 Feb 14;32(2):162-169.e3
pubmed: 38211583
Clin Vaccine Immunol. 2010 Jul;17(7):1055-65
pubmed: 20463105
Nature. 2020 Dec;588(7839):682-687
pubmed: 33045718
Nature. 2022 Aug;608(7923):603-608
pubmed: 35790190
Nat Commun. 2022 Aug 22;13(1):4922
pubmed: 35995780
HIV Med. 2021 May;22(5):372-378
pubmed: 33368966
Nature. 2021 Apr;592(7853):277-282
pubmed: 33545711
Science. 2014 Jan 24;343(6169):428-32
pubmed: 24356113
J Infect Dis. 2021 Jan 4;223(1):23-27
pubmed: 33089317
Nat Rev Microbiol. 2023 Mar;21(3):162-177
pubmed: 36653446
EClinicalMedicine. 2021 Aug;38:100993
pubmed: 34222849
Clin Infect Dis. 2022 Nov 30;75(11):2016-2018
pubmed: 35616095
J Gen Virol. 2021 Apr;102(4):
pubmed: 33855951
Nat Rev Microbiol. 2018 Feb;16(2):80-90
pubmed: 29109555
Nat Commun. 2021 Jul 7;12(1):4196
pubmed: 34234131
Clin Infect Dis. 2004 Apr 15;38(8):1159-66
pubmed: 15095223
N Engl J Med. 2022 Apr 7;386(14):1314-1326
pubmed: 35196424
N Engl J Med. 2020 Dec 3;383(23):2291-2293
pubmed: 33176080
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 May 13;384(19):1824-1835
pubmed: 33440088
Nat Rev Immunol. 2015 Mar;15(3):185-9
pubmed: 25677493
N Engl J Med. 2020 Dec 17;383(25):2439-2450
pubmed: 33053279
Nat Commun. 2022 Dec 13;13(1):7701
pubmed: 36513653
Clin Infect Dis. 2022 Aug 24;75(1):e552-e563
pubmed: 35366316
Emerg Infect Dis. 2021;27(10):2720-2723
pubmed: 34296992
Ann Intern Med. 2020 Oct 6;173(7):536-541
pubmed: 32589451